The protein encoded by SETD1A (SET Domain Containing 1A, Histone Lysine Methyltransferase) is a component of a histone methyltransferase (HMT) complex that produces mono-, di-, and trimethylated histone H3 at Lys4. Literatures have found that SETD1A is required for survival of acute myeloid leukemia (AML) cells. H3K4me3 levels positively correlate with WHO grade malignancy in pediatric EPNs and reduction of H3K4me3 by silencing SETD1A increases cell response to chemotherapy. However, we found that there is no significant differences of SETD1A in different glioma types or grades by analyzing data in TCGA and CGGA databases. Our follow-on plan is to compare the expression of SETD1A in pediatric gliomas, and to find upstream or downstream candidate genes. At the same time, immunohistochemistry and immunoblotting will be used in human glioma tissue and animal models to verify key genes and discover possible targeted genes.
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test
Low-Grade Gliomas also called astrocytomas are the most common cancer of the central nervous system in children. They represent a heterogeneous group of tumors that can be discovered anywhere within the brain or spinal cord. Although surgical resection may be curative, up to 20% of children still su